In a phase 1/2 study, the overall response rate (ORR) was 30.1% for hormone receptor-positive (HR +)/HER2-negative BC (n = 113), 22.6% for TNBC (n = 53), and 42.9% for HER2-positive disease (n = 14). Here, ERBB2 is linked to breast cancer.